Clinical—pharmacological studies on human menopausal gonadotrophin

Publisher Website
Google Scholar
Abstract
Using a randomized, cross-over design, the clinical, pharmacokinetic and pharmacodynamic properties of commercially available gonadotrophin preparations were studied. Following i.v. administration of 150 IU of follicle-stimulating hormone (FSH) in the form of Humegon® Pergonal® and Metrodin®, the maximum concentrations (CMax were 27.5, 24.1 and 26.5 IU/I, respectively which were reached after 15.4, 16.9 and 16.9 mm (TMax respectively. The half lives (t½) were 1.6, 2.3 and 2.0 h, respectively (fast compartment) and 11, 10 and 7.3 h, respectively (slow compartment). The t½ of lutelnizing hormone (LH) could only be estiniated in a surgically hypophysectomized patient: the fast compartment was 1.2 and 1.3 h after the administration of Humegon® and Pergonal®, respectively and the slow compartment was 3.3 h in both cases. Marked individual differences of the same type were found in plasma FSH profiles, ovarian images and peripheral oestradlol levels after the administration of both preparatIons (150 IU daily for 8 days) and the approximate t½ of ESH exceeded 40 h. It is concluded that the pharmacokinetic and pharmacodynamic properties of the preparations studied are similar, if not identical, and that there are marked individual differences in patient responsiveness, which are unrelated to the preparation administered.

This publication has 0 references indexed in Scilit: